

Information for Vermont Prescribers of Prescription Drugs

Daliresp® (roflumilast) Tablets

-- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

-- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher or as calculated from data made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class. (NOTE: As directed by the Vermont Attorney General's Office, the prices listed below are the Wholesale Acquisition Cost ("WAC") plus 20%, or Direct ("DP") plus 20% or Suggested Wholesale Price ("SWP"). All prices reported by third party publisher First Databank. AstraZeneca does not represent that the prices listed below are actual or average transaction prices.)

-- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Product Name			Manufacturer	NDC or UPC	Pkg Size	Pack	Unit
Marketed Product							
Daliresp	250 mcg	Tablet	Astrazeneca	00310-0088-39	20 EA	\$280.46	\$14.02
Daliresp	500 mcg	Tablet	Astrazeneca	00310-0095-30	30 EA	\$420.79	\$14.03
Other Products							
None							

For more information about First Databank's Drug Pricing Policy, <http://www.fdbhealth.com/policies/drug-pricing-policy/>